67804-60-8

Basic information

• Product Name: Ethanone, 1-(2,4-dimethoxyphenyl)-2-(4-methoxyphenyl)-
• CAS NO: 67804-60-8
• Molecular Formula: C17H18O4
• Molecular Weight: 286.328
• Mol File: 67804-60-8.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Ethanone, 1-(2,4-dimethoxyphenyl)-2-(4-methoxyphenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 1-(2,4-dimethoxyphenyl)-2-(4-methoxyphenyl)-(67804-60-8)
• EPA Substance Registry System: Ethanone, 1-(2,4-dimethoxyphenyl)-2-(4-methoxyphenyl)-(67804-60-8)

Safety Data

• Hazardous Substances Data: 67804-60-8(Hazardous Substances Data)

Upstream product

• 119460-65-0 2-(2,4-dimethoxy-phenyl)-2-hydroxy-3-(4-methoxy-phenyl)-propionic acid 
• 39604-64-3 1-(2-hydroxy-4-methoxyphenyl)-2-(4-methoxyphenyl)ethanone 
• 77-78-1 dimethyl sulfate 
• 487-49-0 1-(2,4-dihydroxyphenyl)-2-(4-methoxyphenyl)ethanone 
• 74-88-4 methyl iodide 
• 151-10-0 1,3-Dimethoxybenzene 
• 4693-91-8 4-methoxyphenyl-acetic chloride 
• 14191-95-8 4-cyanomethylphenol 
• 108-46-3 recorcinol 
• 38769-92-5 4-methoxybenzylmagnesium chloride 
• 206051-18-5 N-methoxy-N-methyl-2,4-dimethoxybenzamide 
• 91-52-1 2,4 dimethoxybenzoic acid 
• 104-92-7 1-bromo-4-methoxy-benzene 
• 829-20-9 2',4'-dimethoxyacetophenone 

Downstream Products

• 116665-52-2 2-(2,4-dimethoxy-phenyl)-7-hydroxy-3-(4-methoxy-phenyl)-chromenylium; chloride 
• 94843-20-6 4-(2,4-Dimethoxyphenyl)-5-(4-methoxyphenyl)-1,2,3-thiadiazole 
• 1157-39-7 7-methoxy-3-(4-methoxyphenyl)-4H-chromen-4-one 
• 17720-60-4 2,4,4'-trihydroxy deoxybenzoin 
• 130064-21-0 1-(2-hydroxy-4-((tetrahydro-2H-pyran-2-yl)oxy)phenyl)-2-(4-((tetrahydro-2H-pyran-2-yl)oxy)phenyl)ethanone 
• 1443753-03-4 2-(4-iodophenyl)-7-((tetrahydro-2H-pyran-2-yl)oxy)-3-(4-((tetrahydro-2H-pyran-2-yl)oxy)phenyl)chroman-4-one 
• 1443753-08-9 2-(4-iodophenyl)-4-methyl-7-((tetrahydro-2H-pyran-2-yl)oxy)-3-(4-((tetrahydro-2H-pyran-2-yl)oxy)phenyl)chroman-4-ol 
• 1443753-04-5 3-(4-hydroxyphenyl)-2-(4-iodophenyl)-4-methyl-2H-chromen-7-ol 
• 1443753-05-6 2-(4-iodophenyl)-4-methyl-7-((tetrahydro-2H-pyran-2-yl)oxy)-3-(4-((tetrahydro-2H-pyran-2-yl)oxy)phenyl)-2H-chromene 
• 1352307-39-1 3-(4-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-chromen-7-ol trifluoroacetate 
• 485-72-3 7-Hydroxy-3-(4-methoxy-phenyl)-chromen-4-on 
• 679410-71-0 trifluoromethanesulfonic acid 5-methoxy-2-[2-(4-methoxyphenyl)ethyl]phenyl ester 
• 679410-69-6 4-{5-methoxy-2-[2-(4-methoxyphenyl)ethyl]phenoxy}phenol 
• 679410-72-1 5'-methoxy-2'-[2-(4-methoxyphenyl)ethyl]biphenyl-3-ol 

Relevant articles and documents

Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer

About 75% of breast cancers are estrogen receptor alpha (ER-α) positive, and women typically initially respond well to antihormonal therapies such as tamoxifen and aromatase inhibitors, but resistance often emerges. Fulvestrant is a steroid-based, selective estrogen receptor degrader (SERD) that both antagonizes and degrades ER-α and shows some activity in patients who have progressed on antihormonal agents. However, fulvestrant must be administered by intramuscular injections that limit its efficacy. We describe the optimization of ER-α degradation efficacy of a chromene series of ER modulators resulting in highly potent and efficacious SERDs such as 14n. When examined in a xenograft model of tamoxifen-resistant breast cancer, 14n (ER-α degradation efficacy = 91%) demonstrated robust activity, while, despite superior oral exposure, 15g (ER-α degradation efficacy = 82%) was essentially inactive. This result suggests that optimizing ER-α degradation efficacy in the MCF-7 cell line leads to compounds with robust effects in models of tamoxifen-resistant breast cancer derived from an MCF-7 background.

A new series of estrogen receptor modulators: Effect of alkyl substituents on receptor-binding affinity

New types of selective estrogen receptor modulators (SERMs) were synthesized and evaluated for their binding affinity and biological effect on reproductive cells. A proposed lead structure (B) was derivatized to provide compounds 30 and 44, which showed g

1,2,3-thiadiazole compounds, compositions and method of anti-thrombotic treatment

Novel 1,2,3-thiadiazole compounds, new and old 1,2,3-thiadiazole compositions and method of anti-thrombotic treatment are systemically administered to a human or animal.